No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks' Outcome?
France
rare cancers
reference networks
remoteness
social deprivation
spatial inequalities
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 May 2022
25 May 2022
Historique:
received:
20
04
2022
revised:
15
05
2022
accepted:
23
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
11
6
2022
Statut:
epublish
Résumé
The national reference network NETSARC+ provides remote access to specialized diagnosis and the Multidisciplinary Tumour Board (MTB) to improve the management and survival of sarcoma patients in France. The IGéAS research program aims to assess the potential of this innovative organization to address geographical inequalities in cancer management. Using the IGéAS cohort built from the nationwide NETSARC+ database, the individual, clinical, and geographical determinants of the 3-year overall survival of sarcoma patients in France were analyzed. The survival analysis was focused on patients diagnosed in 2013 (n = 2281) to ensure sufficient hindsight to collect patient follow-up. Our study included patients with bone (16.8%), soft-tissue (69%), and visceral (14.2%) sarcomas, with a median age of 61.8 years. The overall survival was not associated with geographical variables after adjustment for individual and clinical factors. The lower survival in precarious population districts [HR 1.23, 95% CI 1.02 to 1.48] in comparison to wealthy metropolitan areas (HR = 1) found in univariable analysis was due to the worst clinical presentation at diagnosis of patients. The place of residence had no impact on sarcoma patients' survival, in the context of the national organization driven by the reference network. Following previous findings, this suggests the ability of this organization to go through geographical barriers usually impeding the optimal management of cancer patients.
Identifiants
pubmed: 35681600
pii: cancers14112620
doi: 10.3390/cancers14112620
pmc: PMC9179906
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondation ARC pour la Recherche sur le Cancer
ID : PGA1*20160203865
Organisme : French National Cancer Institute
ID : SHSESP16-063
Organisme : SIRIC LYriCAN
ID : grant INCa-DGOS-Inserm_12563
Références
PLoS One. 2018 Apr 5;13(4):e0193330
pubmed: 29621244
Front Oncol. 2019 Apr 08;9:238
pubmed: 31024842
Eur J Cancer. 2016 May;58:90-6
pubmed: 26974708
Int J Cancer. 2019 Mar 15;144(6):1262-1274
pubmed: 30367459
Health Place. 2016 Nov;42:11-18
pubmed: 27614062
Asian Pac J Cancer Prev. 2015;16(3):1259-75
pubmed: 25735366
IARC Sci Publ. 2008;(159):1-259
pubmed: 19517976
Support Care Cancer. 2015 Mar;23(3):741-51
pubmed: 25179691
Cancer Epidemiol. 2016 Aug;43:56-62
pubmed: 27391547
Cancer Epidemiol. 2019 Jun;60:77-85
pubmed: 30927689
Ann Surg Oncol. 2019 Jul;26(7):2286-2293
pubmed: 31065964
Lancet. 2015 Jul 11;386(9989):163-70
pubmed: 25935825
Health Place. 2012 Nov;18(6):1412-21
pubmed: 22906754
Health Place. 2014 Nov;30:36-44
pubmed: 25194994
Lung Cancer. 2014 Mar;83(3):401-7
pubmed: 24491311
J Clin Oncol. 2016 Jan 1;34(1):6-13
pubmed: 26578608
Eur J Public Health. 2013 Oct;23(5):783-8
pubmed: 23345320
PLoS One. 2017 Feb 3;12(2):e0158406
pubmed: 28158190
Eur J Cancer. 2011 Nov;47(17):2493-511
pubmed: 22033323
Cancer. 2012 Nov 1;118(21):5339-48
pubmed: 22517534
Ann Oncol. 2019 Jul 1;30(7):1037-1038
pubmed: 31046083
BMC Cancer. 2012 Aug 13;12:351
pubmed: 22889420
Ann Oncol. 2019 Jul 1;30(7):1143-1153
pubmed: 31081028
Ann Oncol. 2017 Nov 01;28(11):2852-2859
pubmed: 29117335
Cancer. 2008 Feb 15;112(4):909-18
pubmed: 18189295
BMC Cancer. 2010 Apr 19;10:150
pubmed: 20403160
PLoS Med. 2008 Apr 22;5(4):e66
pubmed: 18433290
J Epidemiol Community Health. 2012 Nov;66(11):982-9
pubmed: 22544918
BMC Cancer. 2021 May 27;21(1):620
pubmed: 34039294
Cancer. 2017 Sep 1;123(17):3305-3311
pubmed: 28464212
Ann Oncol. 2004 Feb;15(2):307-15
pubmed: 14760127
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv51-iv67
pubmed: 29846498
Clin Sarcoma Res. 2016 Oct 14;6:18
pubmed: 27777717
JAMA Netw Open. 2020 Aug 3;3(8):e2011087
pubmed: 32766799
Eur J Surg Oncol. 2019 Jan;45(1):16-18
pubmed: 29685758
Cancer Epidemiol. 2017 Aug;49:112-117
pubmed: 28601784
Eur J Surg Oncol. 2019 Jan;45(1):1-2
pubmed: 30041942
Int J Health Geogr. 2009 Jul 23;8:48
pubmed: 19627576
Eur J Cancer. 2006 Nov;42(17):3041-8
pubmed: 17029939
Asian Pac J Cancer Prev. 2014;15(1):25-8
pubmed: 24528034
Pediatr Blood Cancer. 2020 Dec;67(12):e28708
pubmed: 32939963
Int J Health Geogr. 2020 Nov 9;19(1):46
pubmed: 33298076
BMC Cancer. 2013 Oct 24;13:493
pubmed: 24152961
PLoS One. 2021 Feb 25;16(2):e0246958
pubmed: 33630918
BMC Cancer. 2021 May 29;21(1):631
pubmed: 34049529
Acta Oncol. 2020 Feb;59(2):127-133
pubmed: 31702424
Acta Orthop Suppl. 2009 Apr;80(334):1-104
pubmed: 19919379
Int J Environ Res Public Health. 2018 Oct 10;15(10):
pubmed: 30308955
Eur J Cancer. 2014 Jul;50(11):1951-6
pubmed: 24857344
JAMA Intern Med. 2017 Jul 1;177(7):1003-1011
pubmed: 28492829
BMC Cancer. 2020 Mar 6;20(1):190
pubmed: 32138705